J Mitra & Company, based in New Delhi, has launched India’s first Covid-19 Neutralizing Antibody Microlisa Elisa Test its ongoing fight against the corona pandemic. The test kit has cleared all government parameters and received all necessary approvals, including Drug Controller General of India (DCGI) & successful product validation.

Virus neutralization remains the gold standard for determining antibody efficacy. Covid-19 Neutralizing Antibody Microlisa Elisa Test is the first commercial laboratory test to detect neutralizing antibodies against SARS-CoV-2, the virus that causes Covid-19. 

The test kit will help highlight the efficacy of the vaccines on the human body and the development of the antibodies to fight the virus and help identify potential plasma donors. The test kit has high sensitivity (> 95%) and Specificity (100%).

The test identifies individuals who have had recent or prior infection with SARS-CoV-2. Detection of neutralizing antibodies helps us identify its significance for patients as we continue the fight against COVID-19.

Focusing on the performance of the test, Jatin Mahajan, Managing Director, shared, "The test kit has high sensitivity (> 95%) and Specificity (100%). It has a shelf life of 12-months; is easy to use; and provides high throughput of 92 tests in 75 minutes.”